soul trial semaglutide oral cardiovascular outcomes nejm 2025 results Reduces Events in People with Type 2 soul semaglutide Oral and Cardiovascular

Are overweight, with a BMI of 27 kg/m or higher, and have at least one weight-related health condition

49 Melanomas most often occur after puberty and tend to arise at the dermal-epidermal junction, in contrast to the earlier onset and deeper origin of many melanomas arising within large CMN

Increasing the dose too quickly can worsen nausea, vomiting, reflux, diarrhea, or constipation

Understanding the specific cellular pathways and molecular targets could guide future drug development efforts

Next-Generation GLP-1 Agonists (2010s): Liraglutide, Pramlintide, Dulaglutide, and More With the success of exenatide, other GLP-1 analogues rapidly advanced through development

A 2026 UK review of the February 2025 Nature Aging DO-HEALTH trial (1 g/day slowed biological ageing ~4 months), the Framingham red-blood-cell DHA data (~49% lower Alzheimers risk in the top group), the midlife hippocampal-volume study, the ~20% lower dementia risk from dietary omega-3, the APOE4 timing question and the honest atrial-fibrillation caveat with high-dose fish oil versus Dihexas unproven HGF/c-Met synaptogenesis, and why oily fish comes first, not a peptide Read the full review NewNutrition, Diet & Cognitive Neuroscience 4 July 2026 Dihexa for Ultra-Processed Food Brain Fog: UPF, Cognition & the HGF/c-Met Question Can Dihexa undo ultra-processed food brain fog